Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4185-4189

  Zachos, Ioannis ^a   Tzortzis, Vasileios ^a   Mitrakas, Lampros ^a   Samarinas, Michael ^a   Karatzas, Anastasios ^a   Gravas, Stavros ^a   Vandoros, Gerasimos P ^c   Melekos, Michael D ^a   Papavassiliou, Athanasios G ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

BCG; Non muscle invasivebladder cancer; Tumor size; Tumor stage

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TUMOR VOLUME; BLADDER TUMOR; CANCER STAGING; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84902980375     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1547-8     Document Type: Article

References (19)

1. Babjuk M, Oosterlinck W. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59:997-1008. doi:10.1016/j.eururo.2011.03.017.
2. Sylvester RJ, Brausi MA. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766-73. doi:10.1016/j.eururo.2009.12.024.
3. Lee CT. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007;69(6):1068-72. (Pubitemid 46891598)
4. Herr HW. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166(4):1296-9. (Pubitemid 32862159)
5. Zachos I, Konstantinopoulos PA, et al. Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol. 2009;135(9):1169-75. doi:10.1007/s00432-009-0557-9.
6. Sylvester RJ. Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-77.
7. Fernadez Gomes J, Madero R. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195-203. doi:10.1016/j.juro.2009.07. 016.
8. Herr HW. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989;141(1):22-9. (Pubitemid 19028816)
9. Herr HW. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13(6):1404-8.
10. Hurle R. Lowdose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J Urol. 1996;156(5):1602-5. (Pubitemid 26344000)
11. Lebret T. Low-dose BCG, instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol. 1998;34(1):67-72. (Pubitemid 28330339)
12. Ali-El-Dein B, Sooriakumaran P. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int. 2013;111(8):E331-41. doi:10.1111/bju.12026.
13. Martínez-Piñeiro JA, CUETO (Club Urológico Español de Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89(7):671-80. (Pubitemid 34429530)
14. Smits G. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology. 1998;52:1009-14. (Pubitemid 28533368)
15. Bernardini S. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol. 2001;165(1):42-6.
16. Akaza H. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995;75(2):552-9.
17. Davis JW. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol. 2002;167(2 Pt 1):494-500. (Pubitemid 34074513)
18. Orsola A. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005;48(2):231-8. (Pubitemid 40957095)
19. Lebret T. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations. J Urol. 2000;163:63-7.